scholarly journals Clustering subtypes of breast cancer by combining immunohistochemistry profiles and metabolism characteristics measured using FDG PET/CT

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hyun Woo Kwon ◽  
Jeong Hyeon Lee ◽  
Kisoo Pahk ◽  
Kyong Hwa Park ◽  
Sungeun Kim
Keyword(s):  
Breast Cancer ◽  
Glucose Metabolism ◽  
Fdg Pet ◽  
Breast Cancer Subtypes ◽  
Tumor Aggressiveness ◽  
Ki 67 ◽  
Cancer Subtypes ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Metabolic Information

Abstract Background The aim of this study was to investigate the effect of combining immunohistochemical profiles and metabolic information to characterize breast cancer subtypes. Methods This retrospective study included 289 breast tumors from 284 patients who underwent preoperative 18 F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT). Molecular subtypes of breast cancer were classified as Hormonal, HER2, Dual (a combination of both Hormonal and HER2 features), and triple-negative (TN). Histopathologic findings and immunohistochemical results for Ki-67, EGFR, CK 5/6, and p53 were also analyzed. The maximum standardized uptake value (SUV) measured from FDG PET/CT was used to evaluate tumoral glucose metabolism. Results Overall, 182, 24, 47, and 36 tumors were classified as Hormonal, HER2, Dual, and TN subtypes, respectively. Molecular profiles of tumor aggressiveness and the tumor SUV revealed a gradual increase from the Hormonal to the TN type. The tumor SUV was significantly correlated with tumor size, expression levels of p53, Ki-67, and EGFR, and nuclear grade (all p < 0.001). In contrast, the tumor SUV was negatively correlated with the expression of estrogen receptors (r = − 0.234, p < 0.001) and progesterone receptors (r = − 0.220, p < 0.001). Multiple linear regression analysis revealed that histopathologic markers explained tumor glucose metabolism (adjusted R-squared value 0.238, p < 0.001). Tumor metabolism can thus help define breast cancer subtypes with aggressive/adverse prognostic features. Conclusions Metabolic activity measured using FDG PET/CT was significantly correlated with the molecular alteration profiles of breast cancer assessed using immunohistochemical analysis. Combining molecular markers and metabolic information may aid in the recognition and understanding of tumor aggressiveness in breast cancer and be helpful as a prognostic marker.

Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes

2018 ◽  
Vol 39 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Hye Lim Park ◽  
Ie Ryung Yoo ◽  
Joo Hyun O ◽  
Hyoungwoo Kim ◽  
Sung Hun Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Clinical Utility ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Fdg Avidity

139. Relevance of breast cancer subtypes in response monitoring with 18F-FDG PET/CT during neoadjuvant chemotherapy

2012 ◽  
Vol 38 (9) ◽  
pp. 777-778
Author(s):  
B.B. Koolen ◽  
K.E. Pengel ◽  
J. Wesseling ◽  
W.V. Vogel ◽  
M. Vrancken Peeters ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Breast Cancer Subtypes ◽  
Response Monitoring ◽  
Cancer Subtypes ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

7 Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT During Neoadjuvant Chemotherapy

2012 ◽  
Vol 48 ◽  
pp. S42 ◽  
Author(s):  
B.B. Koolen ◽  
K.E. Pengel ◽  
J. Wesseling ◽  
W.V. Vogel ◽  
M. Vrancken Peeters ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Breast Cancer Subtypes ◽  
Response Monitoring ◽  
Cancer Subtypes ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes

PLoS ONE ◽  
2017 ◽  
Vol 12 (5) ◽  
pp. e0176782 ◽  
Author(s):  
Alexander M. Th. Schmitz ◽  
Suzana C. Teixeira ◽  
Kenneth E. Pengel ◽  
Claudette E. Loo ◽  
Wouter V. Vogel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Tumor Response ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes

The Breast ◽  
2016 ◽  
Vol 30 ◽  
pp. 5-12 ◽  
Author(s):  
Tomoko Higuchi ◽  
Arisa Nishimukai ◽  
Hiromi Ozawa ◽  
Yukie Fujimoto ◽  
Ayako Yanai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Prognostic Significance ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Brown adipose tissue (BAT) activation at 18F-FDG PET/CT: correlation with clinicopathological characteristics in breast cancer

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Nadia M. Mostafa ◽  
Nsreen R. A. Mohamadien ◽  
Mohamed H. M. Sayed
Keyword(s):  
Breast Cancer ◽  
Distant Metastasis ◽  
Fdg Pet ◽  
Age Groups ◽  
Clinicopathological Characteristics ◽  
Ki 67 ◽  
Luminal B ◽  
Younger Age ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background There is conflicting results of few published human 18F-FDG PET/CT studies about BAT activation in breast cancer (BC). The aim of the study is to evaluate the association between the levels of BAT metabolic activity detected by 18F-FDG PET/CT and clinicopathological characteristics of a tumor in patients with primary BC. Results BAT was activated in 16 out of 157 (10.2%) consecutive female patients with BC who underwent 18F-FDG PET/CT for initial evaluation. The majority of patients (15/16) had bilateral uptake in the supraclavicular regions. The mean values of the highest SUVmax and total metabolic activity (TMA) of activated BAT were 13.3 ± 9.9 and 79.6 ± 45, respectively. Median outdoor temperature was significantly lower in the activated BAT group (P value=0.035). Patients with BAT activation tended to have a lower median primary tumor size and primary SUVmax, but not statistically significant than those without BAT activation. BAT activation was significantly more frequent among younger age groups (14/16) and patients with lower body mass index (BMI) (10/16), but it was insignificantly more frequent among estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), human epidermal growth factor receptor2 negative (HER2-), invasive ductal carcinoma (IDC), grade II, luminal B subtype, high Ki-67 expression level, patients with positive nodal metastasis, and in patients without distant metastasis. TMA was significantly higher among HER2+ patients (P value=0.019), but insignificantly higher among the younger age groups, stages I and II, invasive lobular carcinoma (ILC), grade I, luminal B subtype, ER+, PR−, higher Ki-67 expression level, patients with positive nodal, and distant metastasis. BMI and patient’s age were the significant independent predictor factors for BAT activation on multivariate regression analysis. Conclusion BAT activation in young age females is sex hormone-dependent, positively associated with less aggressive molecular subtypes of BC, less frequent in patients with distant metastasis. BAT activation may be a prognostic factor that carries a better prognosis in BC.

scholarly journals Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT

2020 ◽  
Vol 66 (5) ◽  
pp. 673-679
Author(s):  
Esra Arslan ◽  
Hale Aral ◽  
Tamer Aksoy ◽  
Çiğdem Usul Afşar ◽  
Senem Karabulut ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Relationship

SUMMARY OBJECTIVE Analyze the over expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD-9) deregulated associated with a poor prognosis in various carcinomas. Our objective was to investigate the relationship between the levels of NEDD-9, CA 15-3, and CEA and PET (SUVmax, MTV40, TLG40) with the clinical parameters of patients with breast cancer (BC). METHODS One hundred and eleven patients (82 BC patients who underwent 18F-FDG PET/CT and 29 healthy controls) were evaluated. SUVmax, MTV, and TLG of the primary tumor were compared with the molecular and histopathological subtypes. 18F-FDG, MTV, and TLG were evaluated based on the clinical data, i.e., nodal involvement, distant metastasis, ER and PR status, Ki-67, serum levels of NEDD-9, CA15-3, and CEA. We compared the NEDD-9 in the BC and healthy control groups. RESULTS The mean ± SD of SUVmax in the 82 patients was 13.0 ± 8.6. A statistically significant relationship (p = 0.022) was found between the molecular subtypes and 18F-FDG uptake. The relationship between 18F-FDG uptake and TLG measured in patients <50 years, ER-PR negativity, and HER2 positivity were statistically significant (p=0.015, 0.007, 0.046, and 0.001, respectively). MTV40, TLG40, and CA 15-3 in metastatic patients were statistically significant (p=0.004, 0.005, and 0.003, respectively). NEDD-9 in the BC group was significantly higher than in the healthy group (p=0.017). There was a positive correlation between SUVmax and Ki67 and CA 15-3; MTV40 and CEA; CA 15-3, CEA, SUVmax, and MTV40; a negative correlation was found between CEA, TLG40, and age. CONCLUSION The use of SUVmax, MTV40, and TLG40 parameters with NEDD-9 and tumor markers has been shown to provide a high diagnostic, predictive, and prognostic value for the management of BC. This is considered to be the basis of interventions focused on the treatment objectives related to NEDD-9.

18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT

2015 ◽  
Vol 54 (04) ◽  
pp. 163-172 ◽  
Author(s):  
A. Piccardo ◽  
M. Puntoni ◽  
S. Morbelli ◽  
F. Bongioanni ◽  
F. Paparo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Fdg Pet ◽  
Whole Body ◽  
Prognostic Impact ◽  
Disease Extent ◽  
Ki 67 ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

SummaryAim: To compare 18F-FDG PET/CT and 18F-NaF PET/CT with respect to disease prognostication and outcome in patients affected by bone metastases from breast cancer (BC). Patients, methods: We retrospectively investigated 32 women with BC and documented bone metastases. Semi-quantitative parameters were applied to 18F-FDG PET/CT and 18F-Na PET/CT in order to evaluate disease extent and tumour metabolism. We used time-to-event analyses (Kaplan Meier and COX proportional hazard methods) to estimate progression-free (PFS) and overall survival (OS) in order to assess the independent prognostic value of 18F-FDG PET/CT and 18F-Na PET/CT. Results: The sensitivity of 18F-NaF PET/CT (100%) was higher (p < 0.05) than that of 18F-FDG PET/CT (72% and 72%). None of the 18F-FDG PET/CT-negative patients showed disease progression at the end of follow-up. After adjustment for age, Ki-67 levels, presence of visceral metastases, hormone therapy, duration of bone disease and response to first-line therapy, only 18F-FDG SUV mean [HR 15.7, 95% confidence interval (CI) 1.15-214.5] and 18F-FDG whole-body bone metabolic burden (WB-B-MB) (HR 16.9; 95%CI 1.87-152.2) were independently and significantly associated with OS. None of the 18F-NaF PET/CT parameters were associated with OS. None of the conventional clinical prognostic parameters remained significantly associated with OS after the inclusion of PET/ CT parameters in the model. Conclusion: 18F-FDG PET/CT is independently associated with OS in BC patients with bone metastases and its prognostic impact seems to be higher than conventional clinical and biological prognostic factors. Although 18F-NaF PET/CT has a higher diagnostic sensitivity than 18F-FDG PET/ CT, it is not independently associated with OS.

scholarly journals The role of FDG-PET-CT in the evaluation of primary systemic therapy in breast cancer: links between metabolic and pathological remission

2012 ◽  
Vol 153 (49) ◽  
pp. 1958-1964 ◽  
Author(s):  
Tímea Tőkés ◽  
Krisztián Somlai ◽  
Borbála Székely ◽  
Janina Kulka ◽  
Gyöngyvér Szentmártoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Primary Tumour ◽  
Axillary Lymph ◽  
Proliferation Marker ◽  
Ki 67 ◽  
Pet Ct ◽  
Fdg Pet Ct

Introduction: FDG-PET-CT is highly sensitive in detection of viable tumour tissue, giving an importance for that in oncological diagnostics. Aim: The authors analysed retrospectively the relationship between metabolic response and changes in Ki-67, a proliferation marker. Methods: Staging FDG-PET-CT scans (before and after therapy) SUVs (Standardized Uptake Value), and morphological changes in the primary tumour and axillary lymph node region were evaluated in 30 patients with breast cancer. Calculated ΔSUV were compared with Ki-67 proliferation marker (measured in biopsies and surgical specimens). Results: The decrease of SUV and size were significant in the primary tumour and the axillary lymph node region. Decrease of Ki-67 was significant. Significant correlation was found between Ki-67 and SUV before therapy, initial Ki-67 and ΔSUV, and ΔKi-67 and ΔSUV. Conclusions: The metabolic changes were more sensitive in the measurement of the therapeutic response than morphological remission, and they correlated well with the pathological response, in not standardized clinical conditions even. Orv. Hetil., 2012, 153, 1958–1964.

Sign in / Sign up

Export Citation Format

Share Document